STIM Neuronetics

Neuronetics and Zion Healing Announce First Franchise Model for TMS Clinics

Neuronetics and Zion Healing Announce First Franchise Model for TMS Clinics

Industry-changing partnership will increase patient access to NeuroStar® Advanced Therapy for Mental Health

MALVERN, Pa. and ST. GEORGE, Utah, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, and Zion Healing, Inc., a leading franchisor of Behavioral Health services and Transcranial Magnetic Stimulation (TMS), announced today a new agreement under which Neuronetics will be the exclusive supplier of TMS equipment to Zion Healing, Inc. and its franchisees. Zion Healing, Inc. is one of the first and only companies to offer a scalable model for franchising of Mental and Behavioral Health Clinics.  

“We cannot open clinics fast enough to meet the needs of this growing market,” said Robert Beatty, CEO of Zion Healing, Inc. “The level of support and training that NeuroStar brings to our franchise model goes well beyond any expectation that we have for an industry partner. The Neuronetics team is simply the best in the industry when it comes to supporting our team and our patients.”

NeuroStar® Advanced Therapy is a non-invasive, non-drug treatment option that uses transcranial magnetic stimulation (TMS) to target key areas of the brain that are underactive in people with depression. NeuroStar is the leading TMS treatment for depression in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar has been proven to be safe and effective with over 4 million treatments delivered to 110,000 patients to date.

“The franchise model that Zion Healing is pioneering has the potential to allow countless more people to receive NeuroStar treatment, at a time when the mental health of so many is suffering,” said Keith J. Sullivan, President and CEO of Neuronetics. “Zion Healing’s unique approach to treating mental health issues, as well as their compassionate approach to patient care, are two of the reasons we wanted to enter into this partnership and are excited about its long-term potential.”

To learn more about NeuroStar® Advanced Therapy, visit . To learn more about Zion Healing, Inc., visit .    

About Neuronetics, Inc.

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience and the largest TMS company in the industry, Neuronetics is redefining patient and physician expectations by designing and developing products that improve the quality of life for people suffering from neurohealth conditions. An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics’ NeuroStar® Advanced Therapy system is today’s leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder in adults with over four million treatments delivered. NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment option that produces extraordinary results. For safety information and indications for use, visit .

Media Contact:

Neuronetics, Inc.

EvolveMKD

646.517.4220

About Zion Healing, Inc.

Zion Healing, Inc. sells and grants Franchises to operate treatment centers for Mental Health Disorders for Youth and Adults to be located generally in regional cities in the United States. Each Franchise will do business and operate under the trademarks of Zion Healing and Zion Healing Centers. The Company has operated varying forms and functions of Residential Inpatient Treatment Centers, Outpatient Services, Counseling, and Mental Health Therapies in Utah for over 8 years under the separate companies of The Retreat at Zion and Zion Recovery. For more information, please visit, .

Media Contact:

Zion Healing Inc. 

Rod Goodman 

208-818-0466 



EN
07/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neuronetics

 PRESS RELEASE

Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter an...

Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basisFull year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basisAchieved positive operating cash flow of $0.9 million in the fourth quarter 2025Ended 2025 with t...

 PRESS RELEASE

Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare...

Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025. T...

 PRESS RELEASE

TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Ag...

TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 States MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, announced that TriWest, the regional administrator for TRICARE, has updated its medical poli...

 PRESS RELEASE

Neuronetics Reports Third Quarter 2025 Financial and Operating Results...

Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% on an adjusted pro forma basis versus Q3 2024 Continued cash management improvement, with cash used in operations of $0.8 million in Q3 2025 Strengthened balance sheet in Q3 2025, ending the quarter with $34.5 million of total cash, consisting of cash, cash equivalents, and restrict...

 PRESS RELEASE

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to twelve new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to the...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch